To assess the possibility that alteration to these components may be contributing to NRF2 activation in ovarian tumors, we evaluated DNA-level alterations affecting the genes involved in this BTRC/SKP1/CUL1 complex. The gene discussed is SKP1; the disease is ovarian neoplasm.